Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Rigel Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Rigel Pharmaceuticals, Inc.’s stock price such as:

• Rigel Pharmaceuticals, Inc.’s current stock price and volume
• Why Rigel Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for RIGL from analysts
• RIGL’s stock price momentum as measured by its relative strength

About Rigel Pharmaceuticals, Inc. (RIGL)

Before we jump into Rigel Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Want to learn more about Rigel Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of June 29, 2026, 10:59 AM, CST, Rigel Pharmaceuticals, Inc.’s stock price was $38.580.

Rigel Pharmaceuticals, Inc. is down 0.28% from its previous closing price of $38.690.

During the last market session, Rigel Pharmaceuticals, Inc.’s stock traded between $38.410 and $39.210. Currently, there are approximately 18.41 million shares outstanding for Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 2.0, which is low compared to the Biotechnology industry median of 19.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Rigel Pharmaceuticals, Inc. Stock Price History

Rigel Pharmaceuticals, Inc.’s (RIGL) price is currently up 26.53% so far this month.

During the month of June, Rigel Pharmaceuticals, Inc.’s stock price has reached a high of $39.230 and a low of $28.460.

Over the last year, Rigel Pharmaceuticals, Inc. has hit prices as high as $52.240 and as low as $18.240. Year to date, Rigel Pharmaceuticals, Inc.’s stock is down 9.92%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Rigel Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 26, 2026, there was 1 analyst who downgraded Rigel Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Rigel Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Rigel Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Rigel Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Rigel Pharmaceuticals, Inc. (RIGL) by visiting AAII Stock Evaluator.

Relative Price Strength of Rigel Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 26, 2026, Rigel Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 23.01%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Rigel Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Rigel Pharmaceuticals, Inc. Stock Price: Bottom Line

As of June 29, 2026, Rigel Pharmaceuticals, Inc.’s stock price is $38.580, which is down 0.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Rigel Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.